<div id="readability-page-1"><p>Diametric Capital LP purchased a new position in shares of  Precigen, Inc. (NASDAQ:PGEN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 335,057 shares of the biotechnology company's stock, valued at approximately $476,000. Diametric Capital LP owned approximately 0.11% of Precigen as of its most recent SEC filing.</p><p>Other hedge funds and other institutional investors have also modified their holdings of the company. Parkman Healthcare Partners LLC acquired a new position in shares of  Precigen during the first quarter worth $4,755,000.  Adage Capital Partners GP L.L.C. lifted its holdings in  Precigen by 3.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company's stock worth $16,801,000 after buying an additional 410,595 shares during the last quarter.  Marshall Wace LLP purchased a new stake in  Precigen during the 2nd quarter worth about $524,000.  Geode Capital Management LLC boosted its position in shares of  Precigen by 7.7% during the 2nd quarter. Geode Capital Management LLC now owns 3,749,182 shares of the biotechnology company's stock worth $5,325,000 after acquiring an additional 269,580 shares in the last quarter.  Finally, Inspire Investing LLC purchased a new position in shares of  Precigen in the 1st quarter valued at about $350,000. 33.51% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Analysts Set New Price Targets</h2><p>Several equities research analysts recently weighed in on PGEN shares. Citigroup  restated an &#34;outperform&#34; rating on shares of Precigen in a research note on Tuesday, August 19th. JMP Securities boosted their price objective on shares of Precigen from $6.00 to $8.00 and gave the stock a &#34;market outperform&#34; rating in a research report on Tuesday, August 19th. Wall Street Zen downgraded shares of Precigen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 15th. HC Wainwright lifted their price target on shares of Precigen from $8.50 to $9.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, November 14th. Finally, JPMorgan Chase &amp; Co. upgraded shares of Precigen from an &#34;underweight&#34; rating to a &#34;neutral&#34; rating in a research note on Friday, August 15th. Four investment analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat.com, Precigen currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $8.50.</p><p><b>Read Our Latest Report on Precigen</b></p><h2>Precigen Stock Down 4.0%</h2><p>PGEN stock opened at $3.60 on Friday. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -2.59 and a beta of 1.16. The company has a fifty day moving average price of $3.81 and a 200 day moving average price of $2.87. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.04 and a quick ratio of 3.95. Precigen, Inc. has a 12 month low of $0.65 and a 12 month high of $5.22. </p><p>Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.03). Precigen had a negative net margin of 3,912.92% and a positive return on equity of 1,066.10%. The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $0.67 million.  Sell-side analysts expect that  Precigen, Inc. will post -0.32 earnings per share for the current year. </p><h2>Insider Buying and Selling at Precigen</h2><p>In related news, CFO Harry Jr. Thomasian acquired 8,284 shares of the firm's stock in a transaction on Thursday, September 25th. The stock was bought at an average cost of $3.62 per share, with a total value of $29,988.08. Following the transaction, the chief financial officer owned 465,694 shares of the company's stock, valued at $1,685,812.28. The trade was a 1.81% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jeffrey B. Kindler sold 106,837 shares of Precigen stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $3.38, for a total value of $361,109.06. Following the completion of the transaction, the director owned 346,070 shares in the company, valued at $1,169,716.60. This trade represents a 23.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders purchased 13,216 shares of company stock valued at $46,816 and sold 9,950,572 shares valued at $37,720,437. 47.10% of the stock is owned by company insiders. </p><h2>Precigen Profile</h2> (Free Report)<p>Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Precigen</li><li>What is the FTSE 100 index? </li><li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li><li>3 Small Caps With Big Return Potential</li><li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li><li>3 Warren Buffett Stocks to Buy Now</li><li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li></ul><p><strong>Want to see what other hedge funds are holding PGEN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Precigen, Inc. (NASDAQ:PGEN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEdFTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEdFTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Precigen Right Now?</h2><p>Before you consider Precigen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.</p><p>While Precigen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PGEN

<p>Diametric Capital LP acquired 335,057 shares of Precigen, Inc. valued at $476,000, owning 0.11% of the company. Analysts have mixed ratings, with a Moderate Buy consensus and an average price target of $8.50. Precigen's stock opened at $3.60, with a market cap of $1.27 billion. Recent insider transactions include CFO Harry Jr. Thomasian buying shares and Director Jeffrey B. Kindler selling shares.</p>

Diametric Capital LP Buys New Holdings in Precigen, Inc. $PGEN